Cuomo, Alessandra
Pirozzi, Flora
Attanasio, Umberto
Franco, Riccardo
Elia, Francesco
De Rosa, Eliana
Russo, Michele
Ghigo, Alessandra
Ameri, Pietro
Tocchetti, Carlo Gabriele http://orcid.org/0000-0001-5983-688X
Mercurio, Valentina
Funding for this research was provided by:
Università degli Studi di Napoli Federico II
Article History
Accepted: 5 November 2020
First Online: 2 December 2020
Compliance with Ethical Standards
:
: Alessandra Cuomo, Umberto Attanasio, Riccardo Franco, Francesco Elia, Eliana De Rosa, Michele Russo, and Flora Pirozzi declare no conflict of interest. Valentina Mercurio has received research funding from SIC/MSD. Alessandra Ghigo is a shareholder and board member of Kither Biotech, a spin-off company focused on the development of PI3K inhibitors for airway disease. Pietro Ameri is supported by an investigator-initiated grant from Boehringer Ingelheim; has received speaker’s honoraria from Novartis, Servier, Daiichi-Sankyo, Pfizer, Boehringer Ingelheim, AstraZeneca, and Merck Sharp & Dohme; and has received compensation for service on advisory boards from Novartis, Daiichi-Sankyo, Bayer, Janssen, and GlaxoSmithKline. Carlo G. Tocchetti has received compensation from Alere for service as a consultant and is listed as an inventor on and receives royalties for Canadian Patent No. 2,613,477 (entitled Thiol-Sensitive Positive Inotropes), issued 3 December 2013, owned by Johns Hopkins University (JHU Ref.: C04755-P04755-05).
: This article does not contain any studies with human or animal subjects performed by the authors.